文献速递肝病

直接抗病毒药物时代丙型肝炎治疗的障碍

Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.
PubMed 文献 · Aliment Pharmacol Ther · 2017-09-26

该回顾性队列研究纳入美国退伍军人事务部84 221例既往已建立丙肝诊疗的HCV感染者,评估直接抗病毒药物(DAA)时代随访与治疗预测因素。47 165例(56.0%)在HCV专科门诊随访,其中13 532例(28.7%)接受DAA;前瞻性招募的905例中56.2%有专科就诊、28%接受DAA。未随访常见原因为搬迁(n=148,37.4%)和错过/取消预约(n=63,15.9%);未治疗原因包括等待新疗法(n=99,38.8%)、合并症(n=66,25.9%)和酒精/药物滥用(n=63,24.7%)。

要点

  • 既往已建立HCV诊疗者中仅56.0%在DAA时代随访,随访者中仅28.7%接受DAA。
  • 未随访常见原因为搬迁(37.4%)和错过/取消预约(15.9%)。
  • 未治疗常见原因为等待新疗法(38.8%)、合并症(25.9%)和酒精/药物滥用(24.7%)。

核心结论

  • 半数既往已建立HCV诊疗的患者在DAA时代得到随访,仅29%接受DAA。
  • 作者认为针对患者和系统层面的靶向努力可能改善新DAA的治疗可及性。

研究设计与样本

  • 回顾性队列研究,使用美国退伍军人事务部HCV感染者临床数据,分析2013年12月1日至2015年4月30日期间HCV门诊随访和DAA治疗的预测因素。
  • 对HCV患者病历进行结构化审查以确定缺乏随访和治疗的原因,并前瞻性招募905例患者。
  • 回顾性队列共纳入84 221例既往在DAA时代前就诊于HCV门诊的退伍军人。

主要发现

  • 84 221例中47 165例(56.0%)在HCV专科门诊随访,其中13 532例(28.7%)接受DAA。
  • 随访的预测因素包括年龄较大、既往治疗、存在肝硬化或HCC、HIV/HBV合并感染和精神疾病。
  • 缺乏治疗的预测因素包括酒精/药物滥用和医学合并症。
  • 前瞻性招募的905例中56.2%有专科就诊、28%接受DAA。
  • 未随访常见原因为搬迁(n=148,37.4%)和错过/取消预约(n=63,15.9%);未治疗常见原因为等待新疗法(n=99,38.8%)、合并症(n=66,25.9%)和酒精/药物滥用(n=63,24.7%)。

关键数值与推荐

  • 随访率56.0%(47 165/84 221),随访者中DAA治疗率28.7%(13 532/47 165)。
  • 前瞻性905例中专科就诊率56.2%、DAA治疗率28%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Direct-acting anti-virals (DAA) are safe, effective treatment of hepatitis C virus (HCV). Suboptimal linkage to specialists and access to DAAs are the leading barriers to treatment; however, data are limited. AIM: To determine predictors of follow-up, receipt of DAAs, and reasons for the lack thereof. METHODS: We used clinical data from retrospective cohort of HCV-infected patients with previously established HCV care in the US Department of Veterans Affairs to examine predictors of follow-up in HCV clinics and DAA treatment (during 12/1/2013-4/30/2015). We then conducted a structured review of medical charts of HCV patients to determine reasons for lack of follow-up and treatment. RESULTS: We identified 84 221 veterans who were previously seen in HCV clinics during the pre-DAA era. Of these, 47 165 (56.0%) followed-up in HCV specialty clinics, 13 532 (28.7%) of whom received DAAs. Older age, prior treatment, presence of cirrhosis or HCC, HIV/HBV co-infection and psychiatric illness were predictors of follow-up. Alcohol/drug abuse and medical co-morbidity were predictors of lack of treatment. Of the 905 prospectively recruited patients, 56.2% patients had a specialist visit and 28% received DAAs. Common reasons for lack of follow-up were relocation (n = 148, 37.4%) and missed/cancelled appointments (n = 63, 15.9%). Reasons for lack of treatment included waiting for newer therapy (n = 99, 38.8%), co-morbidities (n = 66, 25.9%) and alcohol/drug abuse (n = 63, 24.7%). CONCLUSIONS: Half of patients with established HCV care were followed-up in the DAA era and only 29% received DAAs. Targeted efforts focusing on patient and system-levels may improve the reach of treatment with the new DAAs.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lin M, Kramer J, White D, et al. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Aliment Pharmacol Ther. 2017. PMID: 28949020. doi:10.1111/apt.14328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。